^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) + anastrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
HER2-Negative and postmenopausal or premenopausal receiving ovarian ablation or suppression: Preferred Regimens...First-Line therapy, Selective ER down-regulator (fulvestrant, category 1) with/without nonsteroidal aromatase inhibitor (anastrozole, letrozole) (category 1).
Source:
Title:
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
Excerpt:
...Luminal A-like breast cancer (primary or metastatic tumor), defined as: ER-positive, PR-positive (> 20%), Her-2 negative and Ki67 ...
Trial ID:
Source:
Title:
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Excerpt:
...Invasive breast cancer is Human Epidermal Growth Factor Receptor 2 (HER2)- A patient is considered to have HER2 negative breast cancer if one of the following applies:...
Trial ID:
More C2 evidence
Source:
Title:
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Excerpt:
...- ER positive (> 10% of cells) and/or PgR positive (> 10% of the cells) and HER-2 negative disease (IHC 0 or 1+ and/or FISH negative, IHC 2+ and FISH negative)...
Trial ID:
